2013 January to June ≤  ✘approved project brief news

【 Newsletter 1】

On June 26, 2013, Jiangsu Pr÷♠​ovincial Department of Finance and Jiangsu Provin♦↑cial Agricultural Commission jointly issued '★"∏A notice on the deve $¥lopment of provincial modern agriculture - Agr"← ≠icultural industrialization project in≥& 2013, and the "developmen≤≠✔≈t and industrialization pro∑±±ject of Newcastle Disease ™σ§recombinant Virus inactivatedα₽±  vaccine (A-ⅶ strain↑₩‍)" declared by the company was among them, andλ£ε÷ the project obtained a provincial sub♠∑₽sidy fund of 1 million yuδ★an.

According to the latest research, Newcastle di↕±♠εsease virus is the maλ≥in pathogen that causes&γ< Newcastle disease in Chinese duck population ₩✔ in recent years, so the development and ap↔γplication of new Newcastle disease virus vac✔∏★cine is urgent, and the development of ↓≤∏Newcastle disease virus♣♥¥ reverse genetic techn↑∑ ¥ology creates conditi ≥∑ons for the development of new vaccines.

"Newcastle Disease recombinant virus inactivat<Ωσed vaccine (A-Ⅶ strain)" is↑₽★÷ an avian vaccine product d☆×eveloped by the compa←×★ny and Veterinary School of Yangzh‌•™≈ou University through the cooperaε♠↔tion platform of prod★γ‍uction, study and research. The Sc$¥<€hool of Veterinary Medicine of Yangzhou Universi ₹ty adopted advanced reverse gene✘♥tic technology to rescue'↔  for the first time φβA vaccine candidate strain (A≥✔÷ -ⅶ) with the same genotype as th​ ¶∑e epidemic strain. The recombinant NDV (A®✔-ⅶ) was pure and free of®♣δ' foreign sources. At thλλ"e same time, high titer virus antigen was obtaine↓α ↓d by concentrating and purifying with hollow fibe∞≠÷÷r membrane. The product of the project relies on÷¶™β the recombinant Newcastle disea$♥λse virus (A-Ⅶ strain) ♥✘obtained from the Veterinary School of Yangzhou U↔<niversity as the seed •± ←virus, which is harvested by chick★γ‌∑en embryo culture, and the seedק§‍ batch is set up for production. After the chicλ₹ken embryo proliferation, the &✘∏∏harvested disease venom is &δ✔×concentrated, purified, inactivε₹ ∞ated, and then mixed with mineral oil t≈α<₽o form an inactivated vaccine.

The market gap of Newcastle disσδα$ease recombinant virus inactivated vaccα¥ine (A-ⅶ strain) is relatively la¥&✘rge. Through the implementation of this pβ≥roject, the project products will meet t$↔₹δhe market demand to A£<✘ greater extent, increase some employme←≈ ☆nt opportunities, and to a certa$×in extent protect the inteα±rests of farmers and people's ★≥γ"life safety. At the same time,≠β×' this project takes ♦↔♠the lead in introducing largσαe-scale concentration and purification prφπ♥‍oduction technology of ©÷γantigen in the industry. Through the d>πriving and demonstration↑♣≥↓ role of this project, the"™★♦ company's animal va≈☆♦ccine production technology level can be close→™'γ to that of developed countries, while pro ∏₩ moting the overall production level of Chλ₩•ina's animal vaccine industry, it w↔ ill bring benefits to enterp≈♣rises, create profits and taxes for the co"‌®εuntry, and provide protection for peoγγ≈ple's health.

【 Newsletter 2】

After the examination ✔•and approval of Jiangyin Scieφ→nce and Technology Bureau and ™∏Ωtax Bureau, Jiangsu Nan γ←nong High-tech Co., Ltd. continued to e•‌njoy the preferential≈®ππ policies of provincial high-tech enterpγ‍♥≈rises in 2012.

Since the company wa'♣♦↓s identified as a provincial &♠αhigh-tech enterprise by Jia ‌♦ngsu Provincial Science‌≤ε> and Technology Departmen ​<☆t in 2009, the company's brand Ω←¥↓image has been greatly improved↔↑↓, the ability of independent inno✘>δλvation of enterprises has been significantly ←₩enhanced, the business performance has risen sign±↔♦ificantly, and the status of enterprises→₹δγ in the industry has been continuously<©© improved, which provi♦σφ€des a strong qualification guarantφ↔ee for enterprises in the market economy compe₽★tition. It provides guarantee ±≥for the company to achieve susta₽♠inable development.